| Heather Morgan, MS, OTR/L | |
|
30 Main St, Allenstown, NH 03275-2126 | |
| (603) 485-9574 | |
| Not Available |
| Full Name | Heather Morgan |
|---|---|
| Gender | Female |
| Speciality | Occupational Therapist |
| Location | 30 Main St, Allenstown, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447586250 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | 2093 (New Hampshire) | Secondary |
| 225X00000X | Occupational Therapist | 2093 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Heather Morgan, MS, OTR/L 30 Main St, Allenstown, NH 03275-2126 Ph: (603) 485-9574 | Heather Morgan, MS, OTR/L 30 Main St, Allenstown, NH 03275-2126 Ph: (603) 485-9574 |
News Archive
St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) of its AnalyST™ implantable cardioverter defibrillator (ICD) with ST Monitoring, a revolutionary device that not only provides life-saving therapy for dangerously fast heart rhythms, but also continuously monitors electrical changes (called ST segments) to help physicians monitor for cardiac problems.
The American Diabetes Association today strongly expressed its support for federal legislation that would accelerate stem cell research by easing existing restrictions and supporting research that uses embryonic stem cells.
St. Jude Medical, Inc., a global medical device company, today announced it will display a number of new products and clinical solutions from the company's Cardiac Rhythm Management and Atrial Fibrillation Divisions at Heart Rhythm 2010, the Heart Rhythm Society's 31st Annual Scientific Sessions.
Some parents of children with autism evaluate facial expressions differently than the rest of us-and in a way that is strikingly similar to autistic patients themselves, according to new research by neuroscientist Ralph Adolphs of the California Institute of Technology and psychiatrist Joe Piven at the University of North Carolina at Chapel Hill.
Living Cell Technologies, a New Zealand based biotechnology company that is investigating the use of living pig cells in the treatment of diabetes has now received $700,000 (US$500,000) grant from the Juvenile Diabetes Research Foundation International for further human trials.
› Verified 8 days ago